1. Japan Stocks

  2. •

    Healthcare

  3. •

    Medical - Instruments & Supplies
Kitazato Corporation

Kitazato Corporation

368A.T
Kitazato CorporationJP flagTokyo Stock Exchange
1,342.00
JPY
-8.00
- -
53.68BMarket Cap
Kitazato Corporation
368A.T
(Tokyo Stock Exchange)

Recent

price

1,342.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2023
2024
2025
2026
FRC
233.7
252
257.55
273.69
Revenue per Share
84.25
99.3
94.7
97.38
Basic EPS, GAAP
51.25
110.38
65.58
90.78
Free Cash Flow per Basic Share
30
50
40
41
Dividend per Share
352.18
401.5
456.22
512.63
Book Value per Share
350.05
399.55
454.7
511.45
Tangible Book Value per Share
40
40
40
40
Basic Weighted Avg Shares
9,348
10,080
10,302
10,947
Sales/Revenue/Turnover
54.87
58.66
56.13
53.52
Operating Margin (%)
162
177
175
190
Depreciation Expense
3,370
3,972
3,788
3,895
Net Income, GAAP
33.97
33.73
34
34.03
Effective Tax Rate (%)
36.05
39.4
36.77
35.58
Profit Margin (%)
10,050
12,036
13,416
15,717
Working Capital
- -
- -
- -
- -
LT Debt
14,087
16,060
18,249
20,504
Total Equity
- -
- -
- -
- -
Return on Invested Capital (%)
- -
26.36
22.09
20.11
Return on Capital (%)
- -
26.35
22.08
20.1
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
12.36%
Free Cash Flow
- -
- -
38.43%
Net Income, GAAP
- -
- -
2.82%
Sales/Revenue/Turnover
- -
- -
6.26%
Total Cash Common Dividend
- -
- -
2.5%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
10,080
2025
- -
- -
- -
- -
10,302
2026
- -
- -
- -
- -
10,947

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
99.3
2025
- -
- -
- -
- -
94.7
2026
- -
- -
- -
- -
97.38

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
50
2025
- -
- -
- -
- -
40
2026
- -
- -
- -
- -
41
Similar Companies
Shandong Weigao Group Medical Polymer Company Limited (SHWGF)
Anbio Biotechnology Class A Ordinary Shares (NNNN)
Reflect Scientific, Inc. (RSCF)
Bloom Health Partners Inc. (BLMHF)
Autek China Inc. (300595.SZ)
Becton, Dickinson and Company (BDX.SW)
Business
Kitazato Corporation researches, develops, manufactures, and markets medical devices, reagents, and related products for fertility treatment and assisted reproduction technologies. The company offers a comprehensive portfolio covering the entire IVF lifecycle, including oocyte retrieval needles; micro pipettes; embryo transfer (ET) and intrauterine insemination (IUI) catheters such as the RYDEN ET Catheter; culture media and oils like Hypure Oil Heavy; and the proprietary Cryotop Vitrification Method with associated kits including Ultra-Fast Vitri and Ultra-Fast Warming Kit. It supplies over 550 references to more than 3,000 clinics worldwide, with primary operations in Japan and global distribution across Asia, Europe, and other regions. Founded in 1998 and headquartered at 100-10 Yanagishima, Fuji, Shizuoka, Japan, the company, formerly known as Kitazato Biopharma Co., Ltd., listed on the Tokyo Stock Exchange Prime Market in June 2025 under ticker 368A.T following an initial public offering of approximately 14 million shares valued at up to JPY 21.6 billion. Recent developments include the launch of Ultra-Fast Vitrification Protocols and kits, expansion of IVF and andrology media ranges, and attainment of CE marking under EU Medical Device Regulation for the Ultra-Fast Warming Kit, alongside ongoing collaborations with leading clinics for product enhancements and best practice programs.